Beta-2 adrenergic receptor
The beta-2 adrenergic receptor, also known as ADRB2, is a cell membrane-spanning beta-adrenergic receptor that binds epinephrine, a hormone and neurotransmitter whose signaling, via adenylate cyclase stimulation through trimeric Gs proteins, increases cAMP, and, via downstream L-type calcium channel interaction, mediates physiologic responses such as smooth muscle relaxation and bronchodilation.
Robert Lefkowitz and Brian Kobilka's study of the beta-2 adrenergic receptor as a model system earned them the 2012 Nobel Prize in Chemistry "for studies of G-protein-coupled receptors".
The official symbol for the human gene encoding the β2 adrenoreceptor is ADRB2.
Gene
The gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity and type 2 diabetes.Structure
The 3D crystallographic structure of the β2-adrenergic receptor has been determined by making a fusion protein with lysozyme to increase the hydrophilic surface area of the protein for crystal contacts. An alternative method, involving production of a fusion protein with an agonist, supported lipid-bilayer co-crystallization and generation of a 3.5 Å resolution structure.The crystal structure of the β2Adrenergic Receptor-Gs protein complex was solved in 2011. The largest conformational changes in the β2AR include a 14 Å outward movement at the cytoplasmic end of transmembrane segment 6 and an alpha helical extension of the cytoplasmic end of TM5.
Mechanism
This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel CaV1.2. This receptor-channel complex is coupled to the Gs G protein, which activates adenylyl cyclase, catalysing the formation of cyclic adenosine monophosphate which then activates protein kinase A, and counterbalancing phosphatase PP2A. Protein kinase A then goes on to phosphorylate myosin light-chain kinase, which causes smooth muscle relaxation, accounting for the vasodilatory effects of beta 2 stimulation. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling. A two-state biophysical and molecular model has been proposed to account for the pH and REDOX sensitivity of this and other GPCRs.Beta-2 adrenergic receptors have also been found to couple with Gi, possibly providing a mechanism by which response to ligand is highly localized within cells. In contrast, Beta-1 adrenergic receptors are coupled only to Gs, and stimulation of these results in a more diffuse cellular response. This appears to be mediated by cAMP induced PKA phosphorylation of the receptor.
Interestingly, Beta-2 adrenergic receptor was observed to localize exclusively to the T-tubular network of adult cardiomyocytes, as opposed to Beta-1 adrenergic receptor, which is observed also on the outer plasma membrane of the cell
Function
| Function | Tissue | Biological Role |
| Smooth muscle relaxation in: | GI tract | Inhibition of digestion |
| Smooth muscle relaxation in: | Bronchi | Facilitation of respiration. |
| Smooth muscle relaxation in: | Relaxes Detrusor urinae muscle of bladder wall This effect is stronger than the alpha-1 receptor effect of contraction. | Inhibition of need for micturition |
| Smooth muscle relaxation in: | Uterus | Inhibition of labor |
| Smooth muscle relaxation in: | Seminal tract | |
| Increased perfusion and vasodilation | Blood vessels and arteries to skeletal muscle including the smaller coronary arteries and hepatic artery | Facilitation of muscle contraction and motility |
| Increased mass and contraction speed | Striated muscle | Facilitation of muscle contraction and motility |
| Insulin and glucagon secretion | Pancreas | Increased blood glucose and uptake by skeletal muscle |
| Glycogenolysis | Increased blood glucose and uptake by skeletal muscle | |
| Tremor | Motor nerve terminals. Tremor is mediated by PKA mediated facilitation of presynaptic Ca2+ influx leading to acetylcholine release. |
Musculoskeletal system
Activation of the β2 adrenoreceptor with long-acting agents such as oral clenbuterol and intravenously-infused albuterol results in skeletomuscular hypertrophy and anabolism. The comprehensive anabolic, lipolytic, and ergogenic effects of long-acting β2 agonists such as clenbuterol render them frequent targets as performance-enhancing drugs in athletes. Consequently, such agents are monitored for and generally banned by WADA with limited permissible usage under therapeutic exemptions; clenbuterol and other β2 adrenergic agents remain banned not as a beta-agonist, but rather an anabolic agent. These effects are largely attractive within agricultural contexts insofar that β2 adrenergic agents have seen notable extra-label usage in food-producing animals and livestock. While many countries including the United States have prohibited extra-label usage in food-producing livestock, the practice is still observed in many countries.Circulatory system
- Heart muscle contraction
- Increase cardiac output.
- *Increases heart rate in sinoatrial node .
- *Increases atrial cardiac muscle contractility..
- *Increases contractility and automaticity of ventricular cardiac muscle.
- Dilate hepatic artery.
- Dilate arterioles to skeletal muscle.
Eye
- Increase in production of aqueous humour by the ciliary process,
- Subsequent increased pressure-dependent uveoscleral outflow of humour, despite reduced drainage of humour via the Canal of Schlemm.
Digestive system
- Glycogenolysis and gluconeogenesis in liver.
- Glycogenolysis and lactate release in skeletal muscle.
- Contract sphincters of Gastrointestinal tract.
- Thickened secretions from salivary glands.
- Insulin and glucagon secretion from pancreas.
Other
- Inhibit histamine-release from mast cells.
- Increase protein content of secretions from lacrimal glands.
- Receptor also present in cerebellum.
- Bronchiole dilation
- Involved in brain - immune - communication
Ligands
Agonists
Spasmolytics used in [asthma] and COPD">Chronic obstructive pulmonary disease">COPD
- Short-acting β2 agonists
- * bitolterol
- * fenoterol
- * hexoprenaline
- * isoprenaline or isoproterenol
- * levosalbutamol or levalbuterol
- * orciprenaline or metaproterenol
- * pirbuterol
- * procaterol
- * salbutamol or albuterol
- * terbutaline
- Long-acting β2 agonists
- * arformoterol
- * bambuterol
- * clenbuterol
- * formoterol
- * salmeterol
- Ultra-long-acting β2 agonists
- * carmoterol
- * indacaterol
- * milveterol
- * olodaterol
- * vilanterol
[Tocolytic] agents
- Short-acting β2 agonists
- * fenoterol
- * hexoprenaline
- * isoxsuprine
- * ritodrine
- * salbutamol or albuterol
- * terbutaline
β2 agonists used for other purposes
- zilpaterol
Antagonists
- butoxamine*
- First generation β-blockers
- ICI-118,551*
- Propranolol
Allosteric modulators
- compound-6FA, PAM at intracellular binding site
- Cellular swelling
Interactions